AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/570,346

Attorney Docket No.: Q110157

**AMENDMENTS TO THE CLAIMS** 

This listing of claims will replace all prior versions and listings of claims in the

application:

LISTING OF CLAIMS:

1-2 (canceled).

3. (currently amended): A method for screening a compound for development of a

drug for the treatment of Alzheimer's disease, said method comprising:

culturing a neuron expressing APP intracellular C terminal domains (AICD) and (a)

p53 in a culture medium that is supplemented with cisplatin, wherein said neuron is cultured (i)

in the presence of a eandidate compound and (ii) in the absence of the eandidate compound,

respectively, to give cultured neurons;

(b) homogenizing the neuron obtained in step (a) cultured neurons to form a cell

lysate,

(c) contacting the cell lysate with a first antibody, to form an AICD/p53/first

antibody immune complex, wherein said first antibody is selected from the group consisting of

an anti-AICD antibody and an anti-p53 antibody,

(d) detecting and quantifying the AICD/p53/first antibody immune complex from

step (c),

2

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q110157

Application No.: 10/570,346

(e) comparing the amount of the AICD/p53/first antibody immune complex formed in the absence of the eandidate compound with the amount of the AICD/p53/first antibody immune complex formed in the presence of the eandidate compound, and

(f) selecting the eandidate compound that decreases the amount of the AICD/p53/first antibody immune complex compared to the amount of the AICD/p53/first antibody immune complex formed in the absence of the compound, wherein said decrease in the amount of the AICD/p53 complex is indicative of the compound inhibiting binding between AICD and p53.

## 4-12. (canceled).

- 13. (previously presented): The method according to claim 3, wherein the step (d) is conducted by contacting the AICD/p53/first antibody immune complex with a second antibody, wherein the second antibody is selected from an anti-AICD or an anti-p53 antibody and is different from the first antibody.
- 14. (new): The method according to claim 3, wherein said compound is selected from the group consisting of nucleic acid, protein, high molecular weight compound, and low molecular weight compound.